Cardiology
Latest news
974 articles · 20 / page
Ticagrelor vs. Twice-Daily Clopidogrel in STEMI: Insights from the TADCLOT Trial
The TADCLOT trial compared ticagrelor to twice-daily clopidogrel in 2,201 STEMI patients post-PCI. While ticagrelor showed no 30-day superiority in MACE reduction, it demonstrated a significant benefit within the first two weeks with compar
Moving Beyond the 12-Month Default: Personalized DAPT Duration Proven Superior in the PARTHENOPE Trial
The PARTHENOPE randomized trial demonstrates that personalizing DAPT duration (3 to 24 months) based on individual risk scores significantly reduces net adverse clinical events compared to standard 12-month therapy, primarily by lowering is
Echocardiographic Remodeling and Atrial Dynamics with Mavacamten in Nonobstructive Hypertrophic Cardiomyopathy: Insights from the ODYSSEY-HCM Trial
This exploratory analysis of the ODYSSEY-HCM trial demonstrates that mavacamten induces modest regression of left ventricular hypertrophy and improves diastolic and left atrial function in nonobstructive HCM, despite a 21.5% incidence of re
Vericiguat in Compensated HFrEF: Navigating the Complex Results of the VICTOR Trial and the Burden of Outpatient Worsening
The VICTOR trial evaluated vericiguat in stable HFrEF outpatients. While the primary endpoint was not met, exploratory analyses revealed significant mortality reductions and highlighted the prognostic importance of outpatient heart failure
Aficamten Superior to Metoprolol in Redefining the Structural and Hemodynamic Landscape of Obstructive HCM
The MAPLE-HCM trial reveals that aficamten significantly outperforms metoprolol in reducing LVOT gradients and promoting favorable cardiac remodeling in patients with symptomatic obstructive HCM, signaling a potential shift in first-line th
Long-Term ICD Benefits in Nonischemic HFrEF: Why Patient Age and Mode of Death Dictate Clinical Strategy
The extended 13.2-year follow-up of the DANISH trial demonstrates that while primary prevention ICDs do not reduce all-cause mortality in nonischemic HFrEF overall, they significantly lower sudden cardiovascular death risk, particularly in
Novel MicroNet-Covered Stent Sets New Safety Standard for High-Risk Carotid Artery Stenting: Insights from the C-GUARDIANS Trial
The C-GUARDIANS trial reveals that the CGuard MicroNet-covered stent significantly reduces embolic risks in high-risk carotid artery stenting, achieving a remarkably low 30-day DSMI rate of 0.95% and sustained neuroprotection through one ye
Pioneer Valve Demonstrates Mid-Term Efficacy for Pure Aortic Regurgitation in Multicenter Trial
The prospective Pioneer Trial demonstrates that a novel self-expanding TAVR device achieves 99.1% technical success and low mortality (2.7%) at one year for high-risk patients with pure aortic regurgitation, providing a safe, hemodynamicall
Precision Targeting of the Sarcomere: Danicamtiv Shows Genotype-Specific Efficacy in Dilated Cardiomyopathy
A Phase 2 trial demonstrates that danicamtiv, a novel cardiac myosin agonist, significantly improves left ventricular function in patients with genetic forms of dilated cardiomyopathy, particularly those with MYH7 and TTN variants, signalin
Finerenone Extends Cardiorenal Protection Across the Kidney Risk Spectrum in HFmrEF and HFpEF: Insights from FINEARTS-HF
A prespecified analysis of the FINEARTS-HF trial demonstrates that the mineralocorticoid receptor antagonist finerenone consistently reduces cardiovascular death and heart failure events in patients with HFmrEF/HFpEF, regardless of baseline
Finerenone Provides Robust Protection Against Heart Failure Events Regardless of Baseline NYHA Functional Class
A prespecified analysis of the FINEARTS-HF trial confirms that finerenone reduces cardiovascular death and heart failure events in patients with HFmrEF and HFpEF across all symptomatic stages, offering the greatest absolute benefit to those
Sex-Specific Phenotypes and the Evolving Landscape of Aldose Reductase Inhibition in Diabetic Cardiomyopathy: Insights from ARISE-HF
This analysis of the Phase 3 ARISE-HF trial explores sex differences in diabetic cardiomyopathy (DbCM) and the efficacy of AT-001. While women presented with worse exercise capacity and health status at baseline, the novel aldose reductase
Intensive Blood Pressure Control to <120 mmHg: Holistic Benefits Across Frailty, Quality of Life, and Microvascular Health in the ESPRIT Trial
The ESPRIT trial reveals that targeting systolic blood pressure below 120 mmHg significantly reduces cardiovascular events across diverse populations, including frail patients and those with diabetes, while uniquely improving retinal microv
Atherectomy Fails to Improve Limb-Based Outcomes in Chronic Limb-Threatening Ischemia: A Critical Analysis of the BEST-CLI Trial
A secondary analysis of the BEST-CLI trial indicates that atherectomy does not improve outcomes for patients with chronic limb-threatening ischemia undergoing endovascular therapy, with some data even suggesting potential harm in technicall
Interleukin-6 Inhibition: A New Frontier in Reducing Residual Cardiovascular and Renal Risk
Recent clinical evidence identifies Interleukin-6 (IL-6) as a critical driver of cardiovascular events. The ZEUS trial and recent LoDoCo2 analyses suggest that targeting IL-6 with ziltivekimab may significantly reduce risk for patients with
Tenecteplase Outperforms Alteplase in Mechanical Heart Valve Thrombosis: Insights from the TENET Trial
The TENET randomized clinical trial reveals that tenecteplase bolus administration achieves significantly higher thrombolytic success rates and shorter hospital stays compared to alteplase infusion for mechanical prosthetic valve thrombosis
Individualized Blood Pressure Targets vs. Standard Care: Insights from the IMPROVE-multi Trial
The IMPROVE-multi trial found that targeting blood pressure based on preoperative nighttime levels did not reduce postoperative complications compared to a standard MAP target of 65 mm Hg in high-risk abdominal surgery patients.
Opportunistic Genomic Screening for Familial Hypercholesterolemia: Does Genetic Feedback Drive Clinical Change?
This randomized clinical trial investigates whether returning opportunistic genomic results for familial hypercholesterolemia to veterans impacts LDL-C levels. While the primary endpoint missed statistical significance, the findings suggest
Hemodynamic Conservation vs. Obliteration: Why the CHIVA Method and Hybrid Innovations are Redefining Venous Insufficiency Care
This clinical analysis explores the CHIVA method’s role in chronic venous insufficiency, highlighting its superior safety profile and low recurrence rates. By synthesizing Cochrane data and emerging technologies like HIFU, it offers a bluep
Finerenone Reduces Albuminuria via Hemodynamic Mechanisms Rather Than Improving Arterial Stiffness: Insights from the FIVE-STAR Trial
The FIVE-STAR trial demonstrates that while finerenone significantly reduces albuminuria in patients with T2D and CKD, it does not improve arterial stiffness (CAVI). These findings suggest that its cardiorenal benefits are primarily driven
Browse by specialty
Open language-specific specialty feeds and department pages.